Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | FASN | P49327 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (2E,4Z-Decadienoyl)Piperidine SCHEMBL989745 | 1.00 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2ATDP1KDM4E | |
| (2E,4Z-Decadienoyl)Hexamethleneimine SCHEMBL990447 | 1.00 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2ATDP1KDM4E | |
| (2E,4Z-Decadienoyl)Piperidine SCHEMBL989746 | 1.00 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL17091589 | 0.98 | KDM4E (0.49) | L3MBTL1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL30013635 | 0.98 | KDM4E (0.49) | L3MBTL1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL17091590 | 0.98 | KDM4E (0.49) | L3MBTL1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL30013641 | 0.98 | KDM4E (0.49) | L3MBTL1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL30013629 | 0.98 | KDM4E (0.49) | L3MBTL1MEN1KMT2ATDP1KDM4E | |
| (2E,4Z-Decadienoyl)Pyrrolidine SCHEMBL988489 | 0.98 | KDM4E (0.48) | L3MBTL1MEN1KMT2ATDP1KDM4E | |
| Sarmentine SCHEMBL988355 | 0.98 | KDM4E (0.48) | L3MBTL1MEN1KMT2ATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120058640-A | Monomer compound separated from achillea extract, preparation method thereof and application thereof in delaying ovarian aging and improving fertility | 首都医科大学 | 2025-05-30 | — | — | CN | claimed |
| US-20250066320-A1 | Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same | SYMRISE AG (DE) | 2025-02-27 | — | — | US | claimed |
| EP-3969163-B1 | BIODEGRADABLE POLYUREA/POLYURETHANE MICROCAPSULES | SYMRISE AG (DE) | 2024-12-11 | — | — | EP | claimed |
| EP-4452941-A1 | ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME | Symrise AG (DE) | 2024-10-30 | — | — | EP | claimed |
| CN-115043792-B | Achillea millefolium extract, monomer compound of Achillea millefolium extract, and preparation method and application thereof | 首都医科大学 | 2023-11-07 | — | — | CN | claimed |
| EP-4229639-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS Global Biopharma, Inc. (CA) | 2023-08-23 | — | — | EP | claimed |
| CN-115043792-A | Achillea millefolium extract, achillea millefolium extract monomer compound, and preparation method and application thereof | 首都医科大学 | 2022-09-13 | — | — | CN | claimed |
| WO-2022081889-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS GLOBAL BIOPHARMA, INC. (CA) | 2022-04-21 | — | — | WO | claimed |
| EP-4192614-B1 | PROCESS FOR THE PREPARATION OF MICROCAPSULES | SYMRISE AG (DE) | 2026-05-06 | — | — | EP | disclosed |
| CN-120058640-B | Monomer compound separated from achillea extract, preparation method thereof and application thereof in delaying ovarian aging and improving fertility | 首都医科大学 | 2025-12-09 | — | — | CN | disclosed |
| CN-120058640-A | Monomer compound separated from achillea extract, preparation method thereof and application thereof in delaying ovarian aging and improving fertility | 首都医科大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-120058640-A | Monomer compound separated from achillea extract, preparation method thereof and application thereof in delaying ovarian aging and improving fertility | 首都医科大学 | 2025-05-30 | — | — | CN | disclosed |
| US-20250144589-A1 | Method for Producing Microcapsules | SYMRISE AG (DE) | 2025-05-08 | — | — | US | disclosed |
| CN-116322326-B | Polyurea/polyurethane microcapsules | 西姆莱斯股份公司 | 2025-05-02 | — | — | CN | disclosed |
| US-7329767-B2 | Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329767-B2 | Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20080008810-A1 | CONJUGATED DIENAMIDES, METHODS OF PRODUCTION THEREOF, COMPOSITIONS CONTAINING SAME AND USES THEREOF | INTERNATIONAL FLAVORS & FRAGRANCES INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080008810-A1 | CONJUGATED DIENAMIDES, METHODS OF PRODUCTION THEREOF, COMPOSITIONS CONTAINING SAME AND USES THEREOF | INTERNATIONAL FLAVORS & FRAGRANCES INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080008811-A1 | CONJUGATED DIENAMIDES, METHODS OF PRODUCTION THEREOF, COMPOSITIONS CONTAINING SAME AND USES THEREOF | INTERNATIONAL FLAVORS & FRAGRANCES INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080008811-A1 | CONJUGATED DIENAMIDES, METHODS OF PRODUCTION THEREOF, COMPOSITIONS CONTAINING SAME AND USES THEREOF | INTERNATIONAL FLAVORS & FRAGRANCES INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066320-A1 | Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same | TAS2R5, TAS2R7, TAS2R8 | L3MBTL1 4877/4885MEN1 714/4885KMT2A 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.